Tuesday, December 24, 2019 4:35:51 AM
BXDX Meloxicam IV formulation incorporates ALKS Nanocrystal technology
Recent ALKS News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 10/24/2024 01:15:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2024 11:05:11 AM
- Alkermes plc Reports Third Quarter 2024 Financial Results • PR Newswire (US) • 10/24/2024 11:00:00 AM
- Alkermes plc Reports Third Quarter 2024 Financial Results • PR Newswire (US) • 10/24/2024 11:00:00 AM
- Alkermes to Report Third Quarter Financial Results on October 24, 2024 • PR Newswire (US) • 10/17/2024 08:00:00 PM
- Alkermes to Report Third Quarter Financial Results on October 24, 2024 • PR Newswire (US) • 10/17/2024 08:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/09/2024 08:07:13 PM
- Alkermes to Host Investor Event to Review Orexin Portfolio Strategy • PR Newswire (US) • 09/25/2024 12:00:00 PM
- Alkermes to Present Positive Clinical Data From Phase 1b Study of ALKS 2680 in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia at Sleep Europe 2024 • PR Newswire (US) • 09/23/2024 11:00:00 AM
- Alkermes to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Conference • PR Newswire (US) • 09/19/2024 08:00:00 PM
- Alkermes Announces Launch of 7th Annual Alkermes Pathways Research Awards® Program • PR Newswire (US) • 09/13/2024 11:00:00 AM
- Alkermes Announces Launch of 7th Annual Alkermes Pathways Research Awards® Program • PR Newswire (US) • 09/13/2024 11:00:00 AM
- Alkermes to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference • PR Newswire (US) • 08/28/2024 08:00:00 PM
- Alkermes to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference • PR Newswire (US) • 08/28/2024 08:00:00 PM
- Alkermes Announces Initiation of Vibrance-2 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 2 • PR Newswire (US) • 08/22/2024 11:00:00 AM
- Alkermes Announces Initiation of Vibrance-2 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 2 • PR Newswire (US) • 08/22/2024 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/05/2024 08:13:44 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 07/24/2024 08:59:29 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 07/24/2024 01:23:48 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/24/2024 11:05:12 AM
- Alkermes plc Reports Second Quarter 2024 Financial Results • PR Newswire (US) • 07/24/2024 11:00:00 AM
- Alkermes to Report Second Quarter Financial Results on July 24, 2024 • PR Newswire (US) • 07/17/2024 08:00:00 PM
- Alkermes to Report Second Quarter Financial Results on July 24, 2024 • PR Newswire (US) • 07/17/2024 08:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/11/2024 12:56:20 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/11/2024 12:55:11 AM
FEATURED Element79 Gold Corp Shares Further Advances With Chachas Community on Lucero Surface Rights, Provides Corporate Update • Oct 28, 2024 10:25 AM
VAYK Clarifies It Has No Business Connection to Persons Under SEC Charge • VAYK • Oct 28, 2024 11:59 AM
Vocodia Enters Medical Alert Industry with Innovative Emergency Response Pendant • VHAI • Oct 25, 2024 8:00 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for Third Quarter 2024 • HYDI • Oct 24, 2024 11:18 AM
VAYK Asserts Goal of Q4 Operationally Profitable and Projects Major 2025 Launch • VAYK • Oct 24, 2024 10:40 AM
CBD Life Sciences Inc. (CBDL) Positioned for Significant Growth Amid Nationwide Marijuana Legalization Push • CBDL • Oct 24, 2024 7:07 AM